UK Campaign to Stop Genetically Modified Human Embryos
By Marcy Darnovsky,
Genetic Crossroads
| 02. 28. 2007
The UK-based Human Genetics Alert (HGA) has launched a campaign to prevent Britain from becoming the first country in the world to sanction the production of genetically modified human embryos. As reported in the January issue of Genetic Crossroads, a bill set to be introduced would allow British scientists to begin developing technologies that could be used in efforts toward inheritable genetic modification.
Speaking at an HGA press conference, Dr. Richard Nicholson, editor of the Bulletin of Medical Ethics, said, "Every country that has legislated on this subject has banned it. Thus the British Government's decision breaks ranks with the international community, and may lead to the perception that Britain is a haven for irresponsible and profit-driven scientists."
The proposed law maintains the UK's existing ban on creating genetically modified children. But although the white paper supporting the proposed legislation says that genetically altering eggs, sperm and embryos "should not be permitted for reproductive purposes," it adds that this is only "for the foreseeable future, and until such time as safety and efficacy are assured."
HGA Director Dr...
Related Articles
Not the species, certainly, but the Institute of that name, which was founded by transhumanist philosopher Nick Bostrom in 2005 as a research group at Oxford University. According to a recently posted Final Report, its goal was “to pursue the big questions in a transdisciplinary way” by pulling together “researchers from disciplines such as philosophy, computer science, mathematics, and economics.” This evolved before long into the study and promotion of “effective altruism” and “longtermism” as...
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...